Noticed this article about a current trial in Hong Kong using Autologous CAR-T cells, which were produced in Hong Kong in two weeks. The article also describes the cost associated with previously having the patients modified cells grown in the US, and why time is off the essence with respect to disease progression, noting that Azer-Cel would be ready to go.
Speaking purely on blood cancers and leaving oncarlytics aside, Azer-Cel looks quite attractive to me, particularly given the results on patients that have relapsed and have no other options.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)